. Purpose-built bioconjugation facility in Lonza’s Ibex® Dedicate Biopark in Visp, Switzerland to support the potential commercial launch of Kodiak’s lead product candidate KSI-301 for high-prevalence retinal diseases The opening ceremony took place on May 17, 2022 following mechanical completion of the facility in March 2022 Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed […]
continue reading